At the 5-year time point , there were no significant differences in any clinical metric including ischemia-driven target lesion revascularization ( TLR ; ZoMaxx 10.6 % vs. Taxus 7.1 % ; P = 0.29 ) , Q-wave myocardial infarction ( ZoMaxx 1.5 % vs. Taxus 1.0 % ; P = 0.99 ) , definite/probable stent thrombosis ( ZoMaxx 1.5 % vs. Taxus 3.0 % ; P = 0.34 ) , and cardiac death ( ZoMaxx 3.0 % vs. Taxus 1.0 % ; P = 0.28 ) .
